5FA Stock Overview
Engages in the medical devices, pharmaceuticals, and pharma packaging businesses.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
Nipro Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥7.20 |
| 52 Week High | JP¥7.75 |
| 52 Week Low | JP¥6.30 |
| Beta | 0.052 |
| 1 Month Change | 1.41% |
| 3 Month Change | -1.37% |
| 1 Year Change | 9.09% |
| 3 Year Change | -29.41% |
| 5 Year Change | n/a |
| Change since IPO | -25.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5FA | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -0.7% | 1.3% | -0.5% |
| 1Y | 9.1% | -0.3% | 1.8% |
Return vs Industry: 5FA exceeded the German Medical Equipment industry which returned -0.3% over the past year.
Return vs Market: 5FA exceeded the German Market which returned 1.8% over the past year.
Price Volatility
| 5FA volatility | |
|---|---|
| 5FA Average Weekly Movement | 3.6% |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 5FA has not had significant price volatility in the past 3 months.
Volatility Over Time: 5FA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1947 | 38,770 | Yoshihiko Sano | www.nipro.co.jp |
Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses. Its Medical Device business develops, manufactures, and sells medical equipment for injection-infusion and dialysis treatment, and products related to diabetes and cell cultures, as well as the sale of artificial organ-related products. The company’s Pharmaceutical business provides pharmaceutical combination products, including dual chamber bags, pre-filled syringes, and half-type kits; and contract manufacturing services for orally administered drugs, injectables, and external preparations, as well as logistic and distribution services.
Nipro Corporation Fundamentals Summary
| 5FA fundamental statistics | |
|---|---|
| Market cap | €1.19b |
| Earnings (TTM) | €65.63m |
| Revenue (TTM) | €3.47b |
18.2x
P/E Ratio0.3x
P/S RatioIs 5FA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5FA income statement (TTM) | |
|---|---|
| Revenue | JP¥586.79b |
| Cost of Revenue | JP¥415.47b |
| Gross Profit | JP¥171.32b |
| Other Expenses | JP¥160.21b |
| Earnings | JP¥11.11b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 08, 2024
| Earnings per share (EPS) | 68.11 |
| Gross Margin | 29.20% |
| Net Profit Margin | 1.89% |
| Debt/Equity Ratio | 224.5% |
How did 5FA perform over the long term?
See historical performance and comparison